FDA Fully Approves Retevmo for RET Fusion-Positive Medullary Thyroid Cancer

The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric ...

SEPTEMBER 30, 2024

FDA Grants Traditional Approval to Retevmo for RET Fusion–Positive Thyroid Cancer

The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric ...

JUNE 14, 2024

Retevmo Approved for Pediatric Patients with RET-altered Metastatic Thyroid Cancer or Solid Tumors

The FDA has granted accelerated approval to selpercatinib (Retevmo, Lilly.

MAY 30, 2024

Retevmo Approved for RET-Driven NSCLC and Thyroid Cancers

The FDA granted accelerated approval to the selective RET kinase inhibitor selpercatinib (Retevmo, Lilly) for ...

MAY 14, 2020

Thyroid Ca Pts Diagnosed Before 40 Face Higher Risks

Orlando, Fla.—Previous studies have shown that thyroid cancer is associated with an increased risk for ...

JUNE 8, 2017

MDM in Thyroid FNA Samples May Help Optimize Surgical Management

In thyroid nodules with multiple driver mutations, the co-occurrence of more than one high-risk mutation correlates ...

DECEMBER 21, 2016

Immunotherapy-Induced Thyroiditis Under Study

Patients treated with checkpoint inhibitors can develop immunotherapy-related thyroid complications, including ...

DECEMBER 14, 2016

Postoperative Social Support Should Be Tailored to Individual Needs

For recovery in postoperative patients with thyroid cancer, social support is important but must be tailored to ...

OCTOBER 17, 2016